Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Monday November 16, 2009

DrStockPick.com Stock Report!

**************************************************************

SNBP, Sinobiopharma Inc., SNBP.OB

SNBP is a fully integrated and highly innovative specialty biopharmaceutical company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world’s fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co., Ltd. in China, SNBP’s current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.

SNBP reported that 23 generic drugs for which the Company has production rights are listed in China’s National Essential Drugs

...

Bristol-Myers Squibb Co. (BMY) intends to split its 83.1% holding in the Nutritional segment which operates under its subsidiary Mead Johnson and develops infant formulas such as Enfamil and other nutritional products. The move is aimed to enable the company to concentrate on its core biopharmaceutical business. The transaction is expected to be accretive to earnings beginning in 2010.  Under the terms of the deal, Bristol-Myers shareholders can exchange some, none or all of their shares of the company for shares of Mead Johnson common stock tax-free and at a discount. On completion, the exchange offer would enable Bristol-Myers to dispose of its entire holding interest in Mead Johnson.  For every $1 of Bristol-Myers stock exchanged, stockholders will get approximately $1.11 worth of Mead shares. The offer is set to expire on Dec 14, unless extended or terminated. Bristol-Myers owns 170 million shares of Mead Johnson. ...

VANCOUVER, BRITISH COLUMBIA — (Marketwire) — 11/09/09 — Global Health Ventures Inc. (OTCBB: GHLV), or the “Company” a Specialty Pharma is pleased to announce today that it has completed the prototype manufacturing of the drug “X-Excite” Global’s male enhancement drug. The manufacturing of the product was carried out under contract with Vida Pharma of Montreal, Canada. Vida Pharma specialized in the designing of the new tablet size, taste, and hardness. The Company has manufactured over 4000 pills from several different incipient and coatings that are all safe for human consumption. These various batches will be tested at the University of British Columbia, Canada for independent evaluation in regards to drugs adsorption, taste, color and hardness. If the samples meet our end goals then the drug will be ready for mass production under the proprietary formula for testing in humans and finally applying for regulatory approval.

The Company plans to

...

Last night the U.S. House of Representatives brought us one large step closer to a national healthcare system. Investors should be cognizant of the financial effects that would follow.

In the extreme short-run, it would be reasonable to assume that the U.S. stock market would react negatively, although short-term price movements are often chaotic. In the intermediate-term, if the legislation goes forward, the healthcare sector should perform at a lower level than in periods prior to national healthcare.

The chart below shows the historical relative price performance of several healthcare sectors versus the S&P 500. They are: biotech ($DJUSBT), pharmaceuticals ($DJUSPR), healthcare providers ($DJUSHP), medical equipment manufacturers ($DJUSAM) and medical supplies ($DJUSMS). The overall healthcare sector is represented by $DJUSHC.

Biotech and pharmaceuticals have underperformed. We expect that relationship to be accentuated. The other sectors are expected to have lower relative performance than before, particularly the healthcare

...

Echo Therapeutics, Inc., a diabetes management company developing a new needle-free Glocose Monitoring System, reports starting a new a clinical study of its Symphony(TM) Transdermal Continuous Glucose Monitoring product. The (tCGM System) study includes patients with Type 1 and Type 2 diabetes. The purpose of the study is to test the performance of its new one-piece, cost-effective biosensor. Echo expects to announce completed results of the study by the fourth quarter of 2009.

Echo’s pilot clinical study will enroll patients that have either type 1 or type 2 diabetes and will compare data obtained from its Symphony tCGM System with data from the “YSI Glucose Analyzer. The study will obtain about 900 data pairs for use in the analyses. The study will be blind to participating subjects and personnel working on the project and will include reference glucose measurements made at roughly 15 minute intervals for 24 hours.

Patrick T.

...

DaVita Inc. (DVA) reported third quarter net income of $110.9 million or $1.06 per share, which was better than the Zacks Consensus Estimate of 99 cents. The company earned $93.9 million or 89 cents in the comparable quarter of 2008.  Revenues for the quarter came in at $1.57 billion, which reflected an 8.3% increase over the year-ago quarter. According to segments, revenues from the Dialysis and Related Lab Services segment for the quarter came in at $1.49 billion as against $1.38 billion in the prior-year quarter. Other - Ancillary Services and Strategic Initiatives segment generated revenues of $83 million as against $69 million in the year-ago quarter. Highlights of the strong display in the reported quarter included consistent volume growth, stable private pricing and strong cash flows.  Total treatments for the quarter came in at approximately 4.34 million, or 54,927 treatments per day, representing a per ...


The Procter & Gamble Company (PG) reported results for the first quarter of fiscal 2010 with earnings of 97 cents per share, in line with the Zacks Consensus Estimate but down 5.8% year-over-year. Net sales for the quarter declined 5.6% year-over-year to $19.8 billion, as a 3% benefit from pricing and 1% benefit from product mix was fully offset by a 3% decline in unit volume -- a 7% unfavorable impact of foreign currency and a 1% impact of divestitures. However, successful product launches, supported by marketing initiatives, contributed to the top line. Organic sales grew 2% during the quarter driven by pricing and product mix. All three Global Business Units (GBU) witnessed revenue declines during the quarter. The Beauty segment declined 5%, with the low single-digit growth in retail hair care volumes offset by the double-digit decline in Professional salon volume and mid-single-digit decline in female ...

Bayer (BAYRY) announced its third quarter results yesterday. Revenues of the group recorded a 7% decline to €7.39 billion from €7.94 billion. The company’s earnings per share from continued operations were €0.78, compared to €0.85 in year-ago period.

Bayer operates through three major segments: Healthcare, accounting for 53.24% of total revenues in the third quarter of 2009; CropScience (15.4%), and Material Science (27.5%) with the remaining 4% coming from other items. While Healthcare segment revenues improved marginally by 3.5%, both cropscience and Material Science fell 8.6% and 20%, respectively.

The Healthcare segment recorded revenues of €3.9 billion compared to €3.8 billion in the corresponding period last year. Both the divisions of Healthcare – pharmaceuticals and consumer health contributed to the growth of the Healthcare segment. Bayer’s primary market, Europe – accounting for 39% of its Healthcare revenues – declined 3%, compared to the year-ago period. The other markets of North America,

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Monday October 26, 2009

DrStockPick.com Stock Report!

PWRM, BCRX

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3 expects to complete phase II clinical

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

DrStockPick.com Watch List!

My Picks for Monday October 26, 2009, are:

**************************************************************

BCRX, BioCryst Pharmaceuticals, Inc.

U.S. President Barack Obama has declared 2009 H1N1 swine flu a national emergency, the White House said on Saturday.

BCRX designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer and inflammatory diseases. BCRX has progressed two novel compounds into late-stage pivotal clinical trials; peramivir, an anti-viral for influenza, and forodesine, a purine nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma

The U.S. Food and Drug Administration (FDA), in response to a request from the U.S. Centers for Disease Control and Prevention,

...